NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
44 hedge funds and large institutions have $4.74M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
65% less capital invested
Capital invested by funds: $13.4M → $4.74M (-$8.64M)
Holders
44
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$31.6K | |
| 2 | +$19.1K | |
| 3 | +$13K | |
| 4 |
Millennium Management
New York
|
+$9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9K |
Top Sellers
| 1 | -$254K | |
| 2 | -$105K | |
| 3 | -$61.5K | |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$17.6K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$4.4K |